This Stock Just Jumped By 8%: Is It Too Late to Buy?
2026-03-13 12:10:00 ET
Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals outside its core therapeutic area of drugs that treat the underlying causes of cystic fibrosis (CF), given the slow commercial uptake of these newer products and recent clinical trial failures, some investors were starting to doubt the company's ability to perform well outside its CF business.
However, the biotech just showed that it has what it takes to do so. Vertex's shares recently jumped by about 8% on strong late-stage clinical trial results for a promising candidate. But is it too late to buy the company's shares now? Let's find out.
Image source: Getty Images.
NASDAQ: VRTX
VRTX Trading
1.0% G/L:
$456.04 Last:
585,474 Volume:
$454.62 Open:
